Hepatobiliary Cancers: Pathobiology and Translational Advances | EK29

Mar 22, 2021 ‐ Mar 24, 2021

Coffee Break

Preview Available

Coffee Break

Mar 23, 2021 6:30pm ‐ Mar 23, 2021 6:40pm

Genomic and Epigenomic Studies of Cholangiocarcinoma and their Clinical Implications

Preview Available

Genomic and Epigenomic Studies of Cholangiocarcinoma and their Clinical Implications

Mar 23, 2021 6:40pm ‐ Mar 23, 2021 7:10pm

• Teh Bin Tean, MD, PhD, Duke-NUS Medical School

Immune Therapies for HCC: is NASH-HCC Responding Different

Preview Available

Immune Therapies for HCC: is NASH-HCC Responding Different

Mar 23, 2021 7:10pm ‐ Mar 23, 2021 7:40pm

• Josep Llovet, MD, PhD, Icahn School of Medicine at Mount Sinai

Short Talk: Heterogeneous Liver Cancer Development Promoted by PTEN Regulated beta-Catenin and SOX9 Signal

Preview Available

Short Talk: Heterogeneous Liver Cancer Development Promoted by PTEN Regulated beta-Catenin and SOX9 Signal

Mar 23, 2021 7:40pm ‐ Mar 23, 2021 7:55pm

• Bangyan L. Stiles, PhD, University of Southern California

Short Talk: Gender Distinct in Genomic Features of HBV-Related Hepatocellular Carcinoma

Preview Available

Short Talk: Gender Distinct in Genomic Features of HBV-Related Hepatocellular Carcinoma

Mar 23, 2021 7:55pm ‐ Mar 23, 2021 8:10pm

• Chungui Xu, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital

Advances in Molecular and Immune Targeting of Hepatobiliary Cancers

Preview Available

Advances in Molecular and Immune Targeting of Hepatobiliary Cancers

Mar 24, 2021 10:00am ‐ Mar 24, 2021 1:05pm

• Gregory J. Gores, MD, Mayo Clinic
• Lopa Mishra, MD, George Washington University

Immunotherapies for Hepatobiliary Cancers: Current Status and Future Perspectives

Preview Available

Immunotherapies for Hepatobiliary Cancers: Current Status and Future Perspectives

Mar 24, 2021 10:00am ‐ Mar 24, 2021 10:30am

• Tim F. Greten, MD, NCI, National Institutes of Health

Developing Clinical Trials of Novel Therapeutic Agents and Treatment Combinations for Intrahepatic Cholangiocarcinoma

Preview Available

Developing Clinical Trials of Novel Therapeutic Agents and Treatment Combinations for Intrahepatic Cholangiocarcinoma

Mar 24, 2021 10:30am ‐ Mar 24, 2021 11:00am

• R. Kate Kelley, MD, University of California, San Francisco

Targeted Agent and Immune-Based Therapies for Hepatocellular Carcinoma

Preview Available

Targeted Agent and Immune-Based Therapies for Hepatocellular Carcinoma

Mar 24, 2021 11:00am ‐ Mar 24, 2021 11:30am

• Bruno Sangro, MD, PhD, Clinica Universidad de Navarra

Coffee Break

Preview Available

Coffee Break

Mar 24, 2021 11:30am ‐ Mar 24, 2021 11:40am